Evidence Intelligence™
- ImpactScore™
- 67
- Slightly Positive
- EvidenceScore™
- 83
- Strong
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 6 studies
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Semaglutide improves cardiorenal outcomes in high-risk diabetes patients
Última actualización 6 de julio de 2026
Key finding
Semaglutide significantly reduced the risk of primary MACE (HR [95% CI] 0.76 [0.62; 0.92], p = 0.0062).
This study evaluated the cardiorenal effects of semaglutide in individuals with type 2 diabetes at high cardiovascular risk, finding significant reductions in major adverse cardiovascular events.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
High Risk
Guarda este estudio en tu Evidence Tracker para encontrarlo facilmente cuando lo necesites.
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
This study evaluated the cardiorenal effects of semaglutide in individuals with type 2 diabetes at high cardiovascular risk, finding significant reductions in major adverse cardiovascular events.
Clinical relevance
These findings are important as they suggest that semaglutide may be an effective treatment option for reducing cardiovascular risks in patients with type 2 diabetes, a population that is often at elevated risk for heart complications. This could lead to improved management strategies for these patients, potentially reducing the burden of cardiovascular disease.
Keep in mind
The study did not show significant effects on cardiovascular death or all-cause mortality. The generalizability of findings may be limited to the specific population studied. Potential confounding factors were not fully explored.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Jingmin Z, Mansoor H, Yang L, et al. Cardiorenal effects of semaglutide in people with type 2 diabetes at high cardiovascular risk. Diabetes, Obesity & Metabolism. 2025;27(10):5706-5715. doi:10.1111/dom.16621
Efectos Principales
Semaglutide significantly reduced the risk of primary MACE (HR 0.76, p = 0.0062).
Semaglutide significantly reduced the risk of expanded MACE (HR 0.80, p = 0.0097).
Semaglutide consistently reduced nephropathy risk (HR 0.64, p = 0.0054).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Semaglutide and All-cause mortality, Cardiovascular death, Composite cardiovascular events (CV death, MI, stroke, HF hospitalization), and 1 more.
This study contributes evidence to
Primary intervention
Semaglutide
Primary outcomes
- All-cause mortality
- Cardiovascular death
- Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
4
Evidence pairs
4
Relationships
2
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
2
Related topics
4
Evidence pairs
86
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 4 evidence relationships
- Includes primary outcome data
- Linked to 2 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
GLP-1 Receptor Agonists and Cardiovascular Outcomes
Evidencia relacionada
Relación de evidencia
GLP-1 Receptor Agonists and Kidney Function
Seguir evidencia
Tema de evidencia
Cardiovascular Risk
Seguir evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- ImpactScore™
- 33
- Slightly Negative
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ConsistencyScore™
- 67
- generally_consistent
Supporting studies: Based on 3 studies
Add to Evidence TrackerComposite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Semaglutide → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Semaglutide → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Evidence Intelligence™
- ImpactScore™
- 86
- Very Positive
- EvidenceScore™
- 86
- Strong
- ConsistencyScore™
- 71
- generally_consistent
Supporting studies: Based on 7 studies
Add to Evidence TrackerEvidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerBuild your personal Evidence Workspace
Create a free account to save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Today's Activity
Your Evidence Workspace
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
La Evidencia Sugiere
- Semaglutide reduced the risk of primary MACE by 24%.
- Expanded MACE risk decreased by 20% with semaglutide.
- Nephropathy risk was reduced by 36%.
A quién se aplica
- Adults with type 2 diabetes.
- Individuals at high cardiovascular risk.
Tener en Cuenta
- Results may not apply to all diabetes populations.
- Further studies are needed to confirm long-term effects.
- The study did not assess the impact on quality of life.
Entre Líneas
- The study did not show significant effects on cardiovascular death or all-cause mortality.
- The generalizability of findings may be limited to the specific population studied.
- Potential confounding factors were not fully explored.
Save this study
Keep this study in your Evidence Tracker so you can easily find it again whenever you need it.
Today's Activity
Your Evidence Workspace
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
Already have an account?
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Cardiovascular Outcomes, GLP-1 Receptor Agonists and Cardiovascular Outcomes.
Relaciones de evidencia relacionadas
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Detailed evidenceEvidence Intelligence™
- ImpactScore™
- 86
- Very Positive
- EvidenceScore™
- 86
- Strong
- ConsistencyScore™
- 71
- generally_consistent
Supporting studies: Based on 7 studies
View evidenceMedications
Detailed evidenceEvidence Intelligence™
- ImpactScore™
- 67
- Slightly Positive
- EvidenceScore™
- 83
- Strong
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 6 studies
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
Cardiovascular Outcomes Evidence Hub
All studies measuring Cardiovascular Outcomes
7 studies
outcome_hubMeasures Cardiovascular Outcomes as a key outcome.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
7 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en el archivo de evidencia
Jump to pre-filtered views in the evidence archive.
All studies on Semaglutide and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Intervention: SemaglutideOutcome: Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
7 results
All studies on Semaglutide and All-cause mortality
Intervention: SemaglutideOutcome: All-cause mortality
6 results
All studies on Semaglutide
Intervention: Semaglutide
7 results
All studies measuring Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Outcome: Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
7 results
All studies measuring All-cause mortality
Outcome: All-cause mortality
6 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists improve cardiovascular outcomes?
Strong Evidence
GLP-1 Receptor Agonists may improve Cardiovascular Outcomes.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
EvidenceScore™ Strong | EvidenceScore™ 85.5 | strong positive | ConsistencyScore™ Generally Consistent | 1 study
- 2
All-cause mortality
EvidenceScore™ Strong | EvidenceScore™ 82.9 | weak positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 11 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve kidney function?
Strong Evidence
GLP-1 Receptor Agonists may improve Kidney Function.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: The available evidence reports mixed findings.
Ranked evidence signals
- 1
Nephropathy progression
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
- Population details are unavailable.
Does Semaglutide improve cardiovascular death?
Strong Evidence
Semaglutide may worsen Cardiovascular death or be associated with harm.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Cardiovascular death
EvidenceScore™ Strong | EvidenceScore™ 79.0 | weak negative | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in archive
Open broader archive views for this relationship.
Related research
Read related research summaries.
Semaglutide may reduce cardiovascular events in non-diabetic patients.Oral semaglutide reduces cardiovascular events in type 2 diabetesHigher semaglutide doses improve glucose control in type 2 diabetesNovel Semaglutide Injection Shows Non-Inferior Glycemic ControlOral semaglutide may improve cardiovascular event prevention in type 2 diabetes.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.